ArticleBritish journal of cancer2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 54 citations in OpenAlex.
- Male breast cancer: from extrapolated practice to evidence-based care.The oncologist · 2026Review
- Gender-Specific Genetic Predisposition to Breast Cancer:Cancers · 2024Review
- Review
- Bone Health Considerations in Breast Cancer.Seminars in oncology nursing · 2022Review
- Management of Male Breast Cancer: The Journey so Far and Future Directions.World journal of oncology · 2021Review
- Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).Therapeutic advances in medical oncology · 2020Article
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.Breast care (Basel, Switzerland) · 2019Review
- Exclusion of Male Patients in Breast Cancer Clinical Trials.JNCI cancer spectrum · 2018Article
- Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso).World journal of surgical oncology · 2018Article
- Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.Scientific reports · 2017Article
- The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study.ESMO open · 2017Article
- Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.Cancer research and treatment · 2016Article
- Article
- Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.The oncologist · 2015Article
- Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis.Journal of hematology & oncology · 2015Article
- Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study.Journal of experimental & clinical cancer research : CR · 2015Article
- Metastatic male breast cancer: a retrospective cohort analysis.Breast care (Basel, Switzerland) · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData regarding the safety and effectiveness of aromatase inhibitors (AIs) as monotherapy or combined with gonadotropin-releasing hormone (GnRH) analogue in male breast cancer are scarce.
methodsIn this retrospective chart review, cases of male breast cancer patients treated with AIs with or without a GnRH analogue were evaluated.
resultsTwenty-three men were included into this case series. Aromatase inhibitors in combination with or without a GnRH analogue were given as first-line therapy in 60.9% and as second-line therapy in 39.1% of patients, respectively. All patients had visceral metastases, whereas in five of them bone lesions coexisted. In all cases AIs were tolerated well, and no case of grade 3 and 4 adverse events was reported. A partial response was observed in 26.1% of patients and stable disease in 56.5%. Median overall survival (OS) was 39 months and median progression-free survival (PFS) was 13 months. Regarding OS and PFS, no significant effects of GnRH analogue co-administration or type of AI were noted.
conclusionOur study shows that AIs with or without GnRH analogues may represent an effective and safe treatment option for hormone-receptor positive, pretreated, metastatic, male breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.